{
    "ticker": "BCRX",
    "name": "BioCryst Pharmaceuticals, Inc.",
    "description": "BioCryst Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative therapeutics for rare diseases. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst focuses on the design and development of small-molecule drugs that can significantly improve patients' lives. The company is well-known for its flagship product, Orladeyo (berotralstat), which is designed to prevent attacks in patients with hereditary angioedema (HAE). BioCryst is committed to advancing treatments in areas with high unmet medical needs, utilizing its proprietary drug development platform to create oral therapies for conditions such as viral infections and genetic disorders. The company's pipeline includes several promising candidates targeting various diseases, showcasing its commitment to scientific innovation and patient care. With a strong emphasis on research and clinical trials, BioCryst aims to deliver breakthrough therapies that can change the standard of care for patients suffering from rare and complex diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "1986",
    "website": "https://www.biocryst.com",
    "ceo": "Jon P. Stonehouse",
    "social_media": {
        "twitter": "https://twitter.com/BioCryst",
        "linkedin": "https://www.linkedin.com/company/biocryst-pharmaceuticals/"
    },
    "investor_relations": "https://investors.biocryst.com",
    "key_executives": [
        {
            "name": "Jon P. Stonehouse",
            "position": "CEO"
        },
        {
            "name": "William A. Sheridan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Orladeyo (berotralstat)"
            ]
        }
    ],
    "seo": {
        "meta_title": "BioCryst Pharmaceuticals, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Explore BioCryst Pharmaceuticals, Inc., a leader in biotechnology focused on developing therapies for rare diseases. Learn about their innovative products and research initiatives.",
        "keywords": [
            "BioCryst",
            "Biotechnology",
            "Pharmaceuticals",
            "Rare Diseases",
            "Orladeyo",
            "Berotralstat"
        ]
    },
    "faq": [
        {
            "question": "What does BioCryst Pharmaceuticals do?",
            "answer": "BioCryst Pharmaceuticals develops innovative therapeutics for rare diseases, focusing on small-molecule drugs."
        },
        {
            "question": "What is BioCryst's main product?",
            "answer": "BioCryst's main product is Orladeyo (berotralstat), used for the prevention of attacks in patients with hereditary angioedema."
        },
        {
            "question": "Where is BioCryst headquartered?",
            "answer": "BioCryst is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "When was BioCryst founded?",
            "answer": "BioCryst was founded in 1986."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "JNJ",
        "CELG"
    ]
}